- Sunitinib rechallenge is feasible in later lines in patients with metastatic renal cell carcinoma (mRCC) with an acceptable safety profile.
Why this matters
- Sunitinib rechallenge can improve outcomes as an alternative treatment option in later lines when novel therapies are not available.
- Retrospective study of 31 patients with mRCC who underwent sunitinib rechallenge and received sunitinib in ≥2 different treatment lines (upfront and rechallenge) during 2010-2017.
- Primary outcome: treatment duration on sunitinib rechallenge.
- Funding: None disclosed.
- Median time between upfront and rechallenge dose was 8.9 months.
- During sunitinib rechallenge and upfront therapy:
- Median treatment duration was 7.2 (95% CI, 4.1-10.3) months and 17.8 (95% CI, 5.2-47.3) months, respectively.
- Median PFS was 5.6 (95% CI, 3.0-8.2) months and 14.2 (95% CI, 1.6-35.8) months, respectively.
- Median OS was 14.7 (95% CI, 9.4-20.0) months and 57.9 (95% CI, 48.8-66.9) months, respectively.
- Objective response rate was 16% and 34%, respectively.
- Most common adverse events overall were fatigue, hypertension, diarrhea, and nausea.
- Most common grade 3-4 toxicity with rechallenge was fatigue, and with upfront sunitinib was hypertension.
- Single-center study.
- Small number of patients.